Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

AVATAR

Financiado

Cerrado

Integrating Genomics and Avatar Mouse Models to Personalize Pancreatic Cancer Tr...

Integrating Genomics and Avatar Mouse Models to Personalize Pancreatic Cancer Treatment The prognosis of patients with metastatic pancreatic cancer (PDAC) is very poor. Recent studies have started to elucidate the genetic landscape of this disease to show that PDAC is a genetically complex, unstable, and heterogeneou... ver más

30/09/2020

HOSPITAL DE FUENLA...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

HOSPITAL DE FUENLABRADA Actividades hospitalarias organismos publicos

TRL 4-5 | 50K€

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-09-30

ERC-ADG-2014: ERC Advanced Grant

I+D

Cerrada hace 10 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

HOSPITAL DE FUENLABRADA

2.00M€ | Lider

OBRAS Y SERVICIOS TEX

162.88K€ | Participante

FUNDACION SECTOR PUBLICO EST...

501.46K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2021-124106OB-I00 TERAPIAS PERSONALIZADAS EN CANCER DE PANCREAS 508K€ Cerrado

PACA-MET Genome wide surveys and functional analysis of pancreatic ca... 2M€ Cerrado

EVO-PDAC Evolutionary dynamics of pancreatic cancer at single-cell an... 174K€ Cerrado

RTI2018-101071-B-I00 FACTORES DE TRANSCRIPCION EN CANCER DE PANCREAS: DE LA BIOLO... 399K€ Cerrado

PA-CSC Molecular characterization and targeted elimination of metas... 2M€ Cerrado

PANCAIM Pancreatic cancer AI for genomics and personalized Medicine 8M€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2015-09-25
Fecha Fin: 2020-09-30

Líder del proyecto

HOSPITAL DE FUENLABRADA Actividades hospitalarias organismos publicos

TRL 4-5 | 50K€

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The prognosis of patients with metastatic pancreatic cancer (PDAC) is very poor. Recent studies have started to elucidate the genetic landscape of this disease to show that PDAC is a genetically complex, unstable, and heterogeneous cancer. However, in-depth analysis of individual patient genomes couple with personalize Avatar mouse models is providing highly effective therapeutic opportunities for the individual patient. Thus, metastatic PDAC appears a candidate disease to implement a genomics-base, personalized treatment approach. In this project, we will conduct an open label, multicenter, randomized phase III study in patients with standard of care resistant metastatic pancreatic cancer aiming to test the hypothesis that an integrated personalized treatment approach improves survival compare to a conventional treatment. Patients randomized to the personalize treatment arm will undergo a biopsy of a metastatic lesion to perform a targeted genome analysis using next generation sequencing. In addition, we will generate a personalize Avatar mouse model from the same patient. We will employ sophisticated bioinformatic analysis as well as mining of drug response-genetic databases to select, for each individual patient, candidate therapeutic targets that will be experimentally tested in the patient´s Avatar model to select the most effective regimen that will ultimately applied to the patient. In addition, based on the genomic data, we will design an individualized monitoring plan for each patient using BEAMing technology to monitor circulating levels of mutated genes. Furthermore, with a discovery goal, we will perform in depth genomic analysis of metastatic PDAC lesions in this cohort of clinically well-annotated patients with Avatar mouse models for therapeutic validation. Overall we expect this work will contribute to our understanding of PDAC and will favourably impact the treatment of this dismal cancer.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores